Sign up to access all valuation multiples
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.
2010
250
LTM Revenue $69.0M
LTM EBITDA -$21.0M
$476M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Formycon has a last 12-month revenue (LTM) of $69.0M and a last 12-month EBITDA of -$21.0M.
In the most recent fiscal year, Formycon achieved revenue of $80.9M and an EBITDA of -$4.8M.
Formycon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Formycon valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $69.0M | XXX | $80.9M | XXX | XXX | XXX |
| Gross Profit | $6.2M | XXX | $17.2M | XXX | XXX | XXX |
| Gross Margin | 9% | XXX | 21% | XXX | XXX | XXX |
| EBITDA | -$21.0M | XXX | -$4.8M | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | -6% | XXX | XXX | XXX |
| EBIT | -$36.0M | XXX | -$27.3M | XXX | XXX | XXX |
| EBIT Margin | -52% | XXX | -34% | XXX | XXX | XXX |
| Net Profit | -$78.1M | XXX | -$146M | XXX | XXX | XXX |
| Net Margin | -113% | XXX | -180% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Formycon's stock price is EUR 24 (or $28).
Formycon has current market cap of EUR 427M (or $495M), and EV of EUR 410M (or $476M).
See Formycon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $476M | $495M | XXX | XXX | XXX | XXX | $-4.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Formycon has market cap of $495M and EV of $476M.
Formycon's trades at 5.9x EV/Revenue multiple, and -99.9x EV/EBITDA.
Equity research analysts estimate Formycon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Formycon has a P/E ratio of -6.3x.
See valuation multiples for Formycon and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $495M | XXX | $495M | XXX | XXX | XXX |
| EV (current) | $476M | XXX | $476M | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | -22.7x | XXX | -99.9x | XXX | XXX | XXX |
| EV/EBIT | -13.2x | XXX | -17.4x | XXX | XXX | XXX |
| EV/Gross Profit | 77.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.3x | XXX | -3.4x | XXX | XXX | XXX |
| EV/FCF | -10.9x | XXX | -7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFormycon's last 12 month revenue growth is 24%
Formycon's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Formycon's rule of 40 is 128% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Formycon's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Formycon and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Growth | -70% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 128% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Formycon acquired XXX companies to date.
Last acquisition by Formycon was XXXXXXXX, XXXXX XXXXX XXXXXX . Formycon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Formycon founded? | Formycon was founded in 2010. |
| Where is Formycon headquartered? | Formycon is headquartered in Germany. |
| How many employees does Formycon have? | As of today, Formycon has 250 employees. |
| Is Formycon publicy listed? | Yes, Formycon is a public company listed on ETR. |
| What is the stock symbol of Formycon? | Formycon trades under FYB ticker. |
| When did Formycon go public? | Formycon went public in 2010. |
| Who are competitors of Formycon? | Similar companies to Formycon include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Formycon? | Formycon's current market cap is $495M |
| What is the current revenue of Formycon? | Formycon's last 12 months revenue is $69.0M. |
| What is the current revenue growth of Formycon? | Formycon revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Formycon? | Current revenue multiple of Formycon is 6.9x. |
| Is Formycon profitable? | Yes, Formycon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Formycon? | Formycon's last 12 months EBITDA is -$21.0M. |
| What is Formycon's EBITDA margin? | Formycon's last 12 months EBITDA margin is -30%. |
| What is the current EV/EBITDA multiple of Formycon? | Current EBITDA multiple of Formycon is -22.7x. |
| What is the current FCF of Formycon? | Formycon's last 12 months FCF is -$43.5M. |
| What is Formycon's FCF margin? | Formycon's last 12 months FCF margin is -63%. |
| What is the current EV/FCF multiple of Formycon? | Current FCF multiple of Formycon is -10.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
